Abstract
The multidrug resistance (MDR) of tumor cells significantly reduces the efficiency of traditional anticancer therapy. Tumor MDR is complex and involves several mechanisms such as decreased drug uptake, increased drug efflux, enhanced drug exocytosis, increased drug detoxification and inactivation by drugmetabolizing enzymes, altered drug targets due to genetic and epigenetic modifications, altered DNA repair, and impaired apoptotic pathways. Implementation of nanoparticles can markedly improve drug delivery through increased stability in the plasma, prolonged half-life, enhanced specificity of transfer, and advanced drug accumulation and retention in the tumor cells. So far, many various types of nanocarriers have been used for the delivery of anticancer agents. These carriers greatly increase anti-tumor effects of cytotoxic agents since drug-carrying nanoparticles are able to reverse MDR. The promising integrative approach in cancer nanotherapy assumes the development of multifunctional delivery systems simultaneously transmitting various agents such as drugs, genes, imaging agents, and targeting ligands in order to enhance anti-tumor toxicity and nanoparticle tracking.
Keywords: Multidrug resistance, cancer chemotherapy, nanoparticles, drug delivery, cytotoxicity, tumor.
Current Pharmaceutical Design
Title:Nanocarriers in Improving Chemotherapy of Multidrug Resistant Tumors: Key Developments and Perspectives
Volume: 23 Issue: 22
Author(s): Dimitry A. Chistiakov, Veronika A. Myasoedova, Alexander N. Orekhov and Yuri V. Bobryshev*
Affiliation:
- Institute for Atherosclerosis Research, Skolkovo Innovative Center, Moscow 121609,Russian Federation
Keywords: Multidrug resistance, cancer chemotherapy, nanoparticles, drug delivery, cytotoxicity, tumor.
Abstract: The multidrug resistance (MDR) of tumor cells significantly reduces the efficiency of traditional anticancer therapy. Tumor MDR is complex and involves several mechanisms such as decreased drug uptake, increased drug efflux, enhanced drug exocytosis, increased drug detoxification and inactivation by drugmetabolizing enzymes, altered drug targets due to genetic and epigenetic modifications, altered DNA repair, and impaired apoptotic pathways. Implementation of nanoparticles can markedly improve drug delivery through increased stability in the plasma, prolonged half-life, enhanced specificity of transfer, and advanced drug accumulation and retention in the tumor cells. So far, many various types of nanocarriers have been used for the delivery of anticancer agents. These carriers greatly increase anti-tumor effects of cytotoxic agents since drug-carrying nanoparticles are able to reverse MDR. The promising integrative approach in cancer nanotherapy assumes the development of multifunctional delivery systems simultaneously transmitting various agents such as drugs, genes, imaging agents, and targeting ligands in order to enhance anti-tumor toxicity and nanoparticle tracking.
Export Options
About this article
Cite this article as:
Chistiakov A. Dimitry, Myasoedova A. Veronika , Orekhov N. Alexander and Bobryshev V. Yuri *, Nanocarriers in Improving Chemotherapy of Multidrug Resistant Tumors: Key Developments and Perspectives, Current Pharmaceutical Design 2017; 23 (22) . https://dx.doi.org/10.2174/1381612823666170407123941
DOI https://dx.doi.org/10.2174/1381612823666170407123941 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Results on A-Ring Modification of 1α,25-Dihydroxyvitamin D3: Design and Synthesis of VDR-Agonists and Antagonists with High Biological Activity
Current Topics in Medicinal Chemistry Management of Incidental Findings in the Era of Next-generation Sequencing
Current Genomics From Pituitary Adenoma to Pituitary Neuroendocrine Tumors: How Molecular Pathways may Impact the Therapeutic Management?
Endocrine, Metabolic & Immune Disorders - Drug Targets Early Life Programming of Obesity: The Impact of the Perinatal Environment on the Development of Obesity and Metabolic Dysfunction in the Offspring.
Current Diabetes Reviews Neuropeptide Receptor Ligands for the Treatment of Schizophrenia: Focus on Neurotensin and Tachykinins
Current Pharmaceutical Design Cigarette Smoking and Hypertension
Current Pharmaceutical Design A Case-Control Study Investigating the Effect of MTHFR C677T Variant on Performance of Elite Athletes
Endocrine, Metabolic & Immune Disorders - Drug Targets Non-Communicable Diseases and Adherence to Mediterranean Diet
Endocrine, Metabolic & Immune Disorders - Drug Targets Intestinal Immunomodulation. Role of Regulative Peptides and Promising Pharmacological Activities
Current Pharmaceutical Design The Leptin System: A Potential Target for Sepsis Induced Immune Suppression
Endocrine, Metabolic & Immune Disorders - Drug Targets Preclinical Profile of Bacopasides From Bacopa monnieri (BM) As An Emerging Class of Therapeutics for Management of Chronic Pains
Current Medicinal Chemistry Castration-resistant Prostate Cancer: Novel Therapeutics Pre- or Post- Taxane Administration
Current Cancer Drug Targets Adipocytes Derived from Human Bone Marrow Mesenchymal Stem Cells Exert Inhibitory Effects on Osteoblastogenesis
Current Molecular Medicine Estrogen Receptor Signaling: Impact on Cell Functions
Current Signal Transduction Therapy The Lag of the Proliferative Aging Clock Underlies the Lifespan-Extending Effect of Calorie Restriction.
Current Aging Science Functional Genome and Proteome Analyses of Cutaneous Autoimmune Diseases
Current Pharmaceutical Design Cannabinoids
Current Drug Targets - CNS & Neurological Disorders Editorial [Hot topic: Membrane Estrogen Receptors (Guest Editor: Paul J. Davis)]
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cyclic Peptides that Govern Signal Transduction Pathways: From Prokaryotes to Multi-Cellular Organisms
Current Topics in Medicinal Chemistry Modular Protein Engineering in Emerging Cancer Therapies
Current Pharmaceutical Design